[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620496":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":29,"responsibleParty":103,"collaborators":11,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":11,"eligibilityCriteria":111,"healthyVolunteers":107,"sex":112,"minAge":113,"maxAge":11,"enrollmentInfo":114,"targetDuration":11,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Atridia Pty Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HRS-6209 Capsules and fulvestrant injection","EXPERIMENTAL",null,[13],"Drug: HRS-6209 Capsules and fulvestrant injection",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DRUG","HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Kathy You","CONTACT","+61 02 9299 0433","kathyyou@atridia.com",{"name":26,"role":22,"phone":27,"phoneExt":11,"email":28},"Ravi Patel","+61 452 363 506","ravi.patel@atridia.com",[30,47,59,68,80,92],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Southern Highlands Private Hospital","RECRUITING","Bowral","New South Wales","2567","Australia","AU",{"type":39,"coordinates":40},"Point",[41,42],150.4204,-34.4775,{"lat":42,"lon":41},[45],{"name":46,"role":22,"phone":11,"phoneExt":11,"email":11},"Sarah Childs",{"facility":48,"status":32,"city":49,"state":34,"zip":50,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"GenesisCare St Leonards","Sydney","2068",{"type":39,"coordinates":52},[53,54],151.20732,-33.86785,{"lat":54,"lon":53},[57],{"name":58,"role":22,"phone":11,"phoneExt":11,"email":11},"Connie Diakos",{"facility":60,"status":32,"city":49,"state":34,"zip":61,"country":36,"countryCode":37,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"GenesisCare Frenchs Forest","2086",{"type":39,"coordinates":63},[53,54],{"lat":54,"lon":53},[66],{"name":67,"role":22,"phone":11,"phoneExt":11,"email":11},"Connie Diakos, Dr",{"facility":69,"status":32,"city":70,"state":71,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Lyell McEwin Hospital","Elizabeth Vale","South Australia",{"type":39,"coordinates":73},[74,75],138.66819,-34.74857,{"lat":75,"lon":74},[78],{"name":79,"role":22,"phone":11,"phoneExt":11,"email":11},"Mark McGregor",{"facility":81,"status":32,"city":82,"state":83,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Ballarat Base Hospital","Ballarat","Victoria",{"type":39,"coordinates":85},[86,87],143.84957,-37.56622,{"lat":87,"lon":86},[90],{"name":91,"role":22,"phone":11,"phoneExt":11,"email":11},"James Ridgwell",{"facility":93,"status":32,"city":94,"state":83,"zip":11,"country":36,"countryCode":37,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Frankston Hospital","Frankston",{"type":39,"coordinates":96},[97,98],145.12291,-38.14458,{"lat":98,"lon":97},[101],{"name":102,"role":22,"phone":11,"phoneExt":11,"email":11},"Jacqui Thomson",{"type":104,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100620496","phase-1-a-trial-of-hrs-6209-205-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-hrs-6209-in-combination-therapy-in-subjects-with-hr-positiveher2-negative-cancer-100620496",false,"NCT07358377","A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive\u002FHER2-Negative Cancer","An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor","Inclusion Criteria\n\n1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.\n2. Adequate bone marrow and other vital organ functions\n3. Adequate liver function tests\n4. HR-positive or HER2-negative solid tumor patients\n\nExclusion Criteria\n\n1. Plan to receive any other anti-tumor therapy during the study.\n2. Active brain metastases .\n3. Have poorly controlled or severe cardiovascular disease, including (1) congestive heart failure.\n4. Previous use of fulvestrant\n5. clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.\n6. With uncontrollable chronic systemic complications (such as severe chronic lung, liver, kidney, or heart disease).\n7. With acute or active tuberculosis infection requiring medication.\n8. Pregnant or lactating women, or females planning to become pregnant During the study.\n9. Known history of clinically significant liver disease, untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen \\[HBsAg\\] or hepatitis B core antibody \\[HBcAb\\] positive","ALL","18 Years",{"count":115,"type":116},15,"ESTIMATED","INTERVENTIONAL",[119],"PHASE1","To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive\u002FHER2-Negative solid tumor.",[122],"Breast Cancer","2026-08-10",{"date":125,"type":126},"2026-08-11","ACTUAL",{"date":128,"type":126},"2026-05-15",{"date":130,"type":116},"2027-11-10",{"name":5,"class":6},6]